AzTrials
AzTrials

Septic ShockeMESHNCT05202938

eMESH Struct. 2022-23

An observational study of Septic Shock and Chronic Heart Failure, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

A flexible energy metabolism matched with the contractile needs of the muscle is essential to a normal heart. Loss of metabolic flexibility and cardiac systolic efficiency coexist in Sepsis-induced Myocardial Dysfunction (SIMD), a phenomenon attributed to mitochondrial dysfunction and mishandling of energy substrates. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Septic Shock, Chronic Heart Failure
What is being tested?
ultrasound cardiography, FDG PET scan and Palmitate PET scan
Type of treatment
Injection or infusion
How many people
32 participants
Where
1 siteCanada
Study dates
21 Jul 2022to 21 Jul 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Patients hospitalized in intensive care unit and coronary unit of the Sherbrooke hospital/CHUS.

Who may be able to join

  • Patients hospitalized in intensive care unit and coronary unit of the Sherbrooke hospital/CHUS.
  • Accepts healthy volunteers: 4 to 6 age- and sex-matched HV will be recruited and imaged at the end of the inclusion window for the assessment of cardiac energy tracer's uptake and as ref. controls.

Who cannot join

  • Pediatric patients
  • Albumin allergy
  • Moribund patients
  • Patients too much unstable for the imaging procedure (clinical judgment)
  • Unavailable tracers, staff, PET scan in a maximum delay of 72 hours

Trial locations and contacts

1 site in 1 country.

Canada1 site, 1 recruiting
  • CHUS

    Sherbrooke, Quebec, J1H5N4

    Recruiting

Other trials in Canada

About this study

Official title: Energy MEtabolism of Septic Heart.

A flexible energy metabolism matched with the contractile needs of the muscle is essential to a normal heart. Loss of metabolic flexibility and cardiac systolic efficiency coexist in Sepsis-induced Myocardial Dysfunction (SIMD), a phenomenon attributed to mitochondrial dysfunction and mishandling of energy substrates. Cardiac positron emission tomography (PET) could allow to quantify non invasively the selection of energy substrates by the hearts in sepsis and will be associated in parallel with functional status (ultrasound cardiography), injury biomarkers, apelinergic and metabolomic blood profiles. Comparisons will be performed between septic and acute on chronic heart failures, with or without systolic dysfunction.

Read the detailed description

Septic shock is both highly prevalent and morbid in the intensive care units. The mortality rate rises from 10-30% to 70-80% with sepsis-induced myocardial dysfunction (SIMD) occurence. SIMD is related to stress-induced cardiomyopathies and features bio-mechanistic components distinctive from chronic heart failure (CHF) traditionally attributed to a coronary disease. Dobutamine, a beta-adrenergic receptor agonist, is the inotrope drug actually recommended when cardiac index is too low, often in association with a mix of alpha-beta-adrenergic agonists like norepinephrine. In this context, dobutamine is marginally effective (1/3 responders), has potential deleterious impacts on function and viability of cardiomyocytes, and induces increased needs in cardiac energy metabolism. The healthy heart works almost exclusively on aerobic metabolism. While glucose is the essential fuel for brain and skeletal muscles, fatty acids through lipid oxidation are the main substrates for a normal resting heart (Randle cycle). This lipid oxidation is producing at least 70% of cardiac ATP, the balance is coming from glucose, with a marginal contribution from ketone bodies and lactate. The mitochondria is a cellular factory which produces more than 95% of body ATP. Mitochondria represent 30-40% of the cardiomyocyte total volume and consume oxygen to generate huge quantities of ATP/day by oxidative phosphorylation through 3 connective pathways: cytoplasmic glycolysis, Krebs cycle, and the mitochondrial electron transport chain inside the respiratory enzymes complex. Although a direct close relationship between myocardial metabolism homeostasis and function is not clearly established in normal condition, a compensatory equilibrium between fatty acid and glucose mitochondrial oxidations is a generally accepted concept. Indeed, the heart is omnivorous and can modulate fuel-substrates captation/utilization according to the physiological events (exercise, fast).That reprogramming capacity towards other various circumstances or pathological conditions is not guaranteed, with potential loss of metabolic flexibility. SIMD is highly prevalent in septic shock and is frequently indicative of a worsened outcome with increased mortality. Left ventricular systolic and diastolic dysfunctions are observed in 50% of acute sepsis within the first 48 hours after patient's admission. Animal experimental models can simulate human sepsis and SIMD by injecting endotoxin (LPS model) or feces in the abdominal cavity (cecal ligation puncture model), and with inflammatory cytokines, oxidative stress, nitric oxide and neutrophils as potential aggressors. Ventriculo-arterial and excitation-contraction decoupling are the hallmark of the contractile inefficiency observed in SIMD. Ca2+ handling (an ion molecule essential for heart function) in aberrant during sepsis and associated with impaired activation/phosphorylation and proteolytic cleavage increased of key regulators like heart troponin I. Resulting common cyto-histopathological damages are: myocardial apoptosis with focal necrosis, cardiac muscle edema, congestion, multiples inflammatory infiltrates, and mitochondrial structural insults with intra-myocardial accumulation of glycogen \& lipids. The lathers could be a spillover effect of the cardiac metabolic shut-down consecutive to mitochondrial dysfunction. A decrease in fatty acid captation/oxidation has been documented in traditional CHF, not always offset by an enhanced use of glucose, but sometimes by an increased use of ketone bodies and lactates, and through an elevated myocardial proteolysis. This observation doesn't necessarily apply to sepsis and SIMD where cardiac energy metabolism is still a mystery. Systemic metabolic alterations in sepsis are complexe, with glycogenolysis and gluconeogenesis activations, insulinoresistance, and an increased lipolysis with enhanced fatty acid blood levels. In these conditions and in the heart, a drop of fatty acid oxidation is not necessarily compensated by an increased glucose use. Different denominations have been used to figure out these SIMD-induced metabolism disorders, the best being "metabolic-bioenergetic shut-down and stunning". In fact, sepsis induces a metabolic hurricane in bloodstream, vital organs and mitochondria, resulting in a significant rise of the rest energy expenditure. Dhainaut et al were first to demonstrate in 1987 a shift in the selection of energy fuels by myocardial tissues in septic shock patients. Both fatty acid and glucose uses were diminished by 4 and 2 times, respectively. However, this study addressed to suboptimally fluid resuscitated patients, who were in early acute hyperdynamic shock (< 6 hours). In experimental mouse models challenged with LPS or cecal ligation puncture, and adequate fluid resuscitation, the cardiac microperfusion is altered (i.e. malperfusion), and mitochondrial oxidative metabolism diminished, with an increase of glucose myocardial uptake. The apelin system is a family of endogenous peptides hormones (the apelins), not related to catecholamines, but with strong cardiovascular properties. This functional impact correlates with the constitutive expression of apelins and their receptor APJ in heart and vessels. Cardiac effects of apelins are characterized by an enhanced contractile force (systolic function), without chronotropic but with a lusitropic effect and a dromo-modulation. Another one impact of the apelins is on the cardiac utilization of metabolic energy substrates.

Apelins are facilitators-influencers glucose and fatty acid usage through recruitment of major specific carriers such as GLUT4 and FAT/CD36.

Research investigations: Which energy source is privileged by cardiac mitochondria in acute septic shock with or without myocardial dysfunction vs non-septic CHF ? Is this tentative shift/move of energy substrate's use related to muscle dysfunction or only reactive to the systemic environment ? and is it specific of sepsis or common to any non-specific myocardial damage ? Is this shift related to a particular biophenotype of the apelinergic system which is involved in the cardiovascular homeostasis ? and/or a distinctive alteration of the cardiac injury biomarkers ? Is the systemic environmental metabolomic affected toward a trending way during acute septic shock ?

Hypotheses: A myocardial positron emission tomography (PET) could allow to visualize and quantify non invasively energy supply selection of hearts in acute shock conditions related or not related to sepsis. Relationships can be found between PET profiles, sources of acute shock (sepsis vs non sepsis), functional data (ultrasound cardiography), cardiac injury specific biomarkers, apelinergic and metabolomic blood profiles.

Objectives: 1) To show the analytical value of the cardiac captation kinetic of 3 energy tracers (palmitate for fatty acids, FDG for glucose and acetate fpr mitochondrial activity), 2) To correlate PET data with myocardial (dys)function observed by US cardiography, 3) To evaluate the patients blood metabolomic profile in terms of products accumulation derived from a failure of energy substrates oxidation, 4) To measure and compare myocardial injury/ remodelling biomarkers (troponins, NT-proBNP, galectin-3) and the systemic endogenous apelin biophenotype.

Methods: 1) Prospective evaluative study of 4 groups of 8 patients in septic shock or in acute heart failure under hemodynamic support: i) a group with evidences of SIMD (US cardiography at the ICU ward in the first 48hrs: systolic ejection fraction < 45%), ii) a group in septic shock without evidence of SIMD, iii) a group with non-septic heart failure (systolic ejection fraction < 45% or cardiac insufficiency with reduced ejection fraction, iv) a group with non-septic (systolic ejection fraction < 50% or cardiac insufficiency with reduced ejection fraction.

Being tested
ultrasound cardiography, FDG PET scan, Palmitate PET scan, Acetate PET scan, Blood sampling
Keywords
Septic shock, Heart dysfunction, Positron emission tomography, Energy substrates (glucose, fatty acid, acetate), Mitochondrial activity
Medical subject headings
Shock, Septic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ultrasound cardiographyDiagnostic test

    Ultrasound to check heart functions and systolic ejection fraction.

  • FDG PET scanDiagnostic test

    Also called FDG positron emission tomography

    FDG venous injection and positron emission tomography scan.

  • Palmitate PET scanDiagnostic test

    Also called Palmitate positron emission tomography

    C11-Palmitate venous injection and positron emission tomography scan.

  • Acetate PET scanDiagnostic test

    Also called Acetate positron emission tomography

    C11-Acetate venous injection and positron emission tomography scan.

  • Blood samplingDiagnostic test

    Also called Collecting blood sample

    Collecting 20ml of venous blood.

Study groups in NCT05202938
Study groupRoleWhat they receive
Septic shock with SIMD: SIMD+8 patients in septic shock (Sepsis-3-) with SIMD: ejection fraction (LVEF) < 45% in the first 48 hours of admission into the intensive care unit. No prior cardiac ultrasound or normal cardiac ultrasound values less than 2 years ago , or an ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine) required to obtain a LVEF ≥ 45%, or a drop of ≥ 20% compared to the LVEF value record ed less than 2 years ago.
Receives: Diagnostic Test: ultrasound cardiography; Diagnostic Test: FDG PET scan; Diagnostic Test: Palmitate PET scan; Diagnostic Test: Acetate PET scan; Diagnostic Test: Blood sampling
Septic shock without SIMD: SIMD-8 patients in septic shock (Sepsis-3) without SIMD. Ejection fraction (LVEF) ≥ 45% with or without ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine), or similar to the LVEF recorded less than 2 years ago.
Receives: Diagnostic Test: ultrasound cardiography; Diagnostic Test: FDG PET scan; Diagnostic Test: Palmitate PET scan; Diagnostic Test: Acetate PET scan; Diagnostic Test: Blood sampling
Acute Heart Failure with reduced Ejection Fraction: HFrEF8 patients with acutely reduced ejection fraction (LVEF) < 50%. with or without ino-vasotropic infusion (milrinone, dobutamine, norepinephrine or epinephrine) No prior cardiac ultrasound, or normal cardiac ultrasound values less than 2 years ago, or a drop of ≥ 20% compared to the LVEF recorded less than 2 years ago. No evidence of sepsis or septic shock.
Receives: Diagnostic Test: ultrasound cardiography; Diagnostic Test: FDG PET scan; Diagnostic Test: Palmitate PET scan; Diagnostic Test: Acetate PET scan; Diagnostic Test: Blood sampling
Acute Heart Failure with preserved Ejection Fraction: HFpEF8 patients with acute heart failure and a preserved ejection fraction (ejection fraction (LVEF ≥ 50% or similar to normal cardiac ultrasound values recorded less than 2 years ago). No evidence of septic shock.
Receives: Diagnostic Test: ultrasound cardiography; Diagnostic Test: FDG PET scan; Diagnostic Test: Palmitate PET scan; Diagnostic Test: Acetate PET scan; Diagnostic Test: Blood sampling

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. FDG PET scan

    Positron emission tomography with FDG radiotracer. It will report the glucose uptake by the heart.

    Measured: 25 minutes

  2. Palmitate PET scan

    Positron emission tomography with C11-palmitate radiotracer. It will report the fatty acid uptake by the heart.

    Measured: 15 minutes

  3. Acetate PET scan

    Positron emission tomography with C11-acetate radiotracer. It will report the acetate uptake by the heart.

    Measured: 10 minutes

  4. Quantitative study of blood FDG:palmitate balance.

    Measure of the blood FDG:palmitate balance by spectroscopy LC-MS and NMR.

    Measured: 20 minutes

Secondary outcomes (3)
  1. Measure of myocardial injury biomarkers.

    Measure of blood myocardial injury biomarkers by immuno-enzymatic methods (Troponin T, NT-pro BNP, Galectin 3

    Measured: 45 minutes

  2. Measure of apelinergics.

    Measure of blood apelinergics (apelin-13 ,apelin-17, apelin-36 and ELABELA) by immuno-enzymatic methods.

    Measured: 45 minutes

  3. Profiling of the systemic metabolomic.

    Profiling of the systemic (blood) metabolomic by LC-MS and NMR. It will report metabolites in blood such as acetate, acetoacetate, acetone, 3-OH-butyrate, citrate, glutamate, lactate and pyruvate.

    Measured: 45 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jan 2022
  2. Study start21 Jul 2022
  3. Primary completion21 Dec 2023 (estimated)
  4. Study completion21 Jul 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
32 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05202938
Sponsor's protocol ID
eMESH struct. 2022-23
Other IDs
2021-4012
Acronym
eMESH
Status last verified
Jul 2023
First submitted
10 Jan 2022
Last updated
20 Jul 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990 Aug 1;113(3):227-42. doi: 10.7326/0003-4819-113-3-227.

    PubMed 2197912
  • Merx MW, Weber C. Sepsis and the heart. Circulation. 2007 Aug 14;116(7):793-802. doi: 10.1161/CIRCULATIONAHA.106.678359.

    PubMed 17698745
  • Walley KR. Sepsis-induced myocardial dysfunction. Curr Opin Crit Care. 2018 Aug;24(4):292-299. doi: 10.1097/MCC.0000000000000507.

    PubMed 29846206
  • Taegtmeyer H, Young ME, Lopaschuk GD, Abel ED, Brunengraber H, Darley-Usmar V, Des Rosiers C, Gerszten R, Glatz JF, Griffin JL, Gropler RJ, Holzhuetter HG, Kizer JR, Lewandowski ED, Malloy CR, Neubauer S, Peterson LR, Portman MA, Recchia FA, Van Eyk JE, Wang TJ; American Heart Association Council on Basic Cardiovascular Sciences. Assessing Cardiac Metabolism: A Scientific Statement From the American Heart Association. Circ Res. 2016 May 13;118(10):1659-701. doi: 10.1161/RES.0000000000000097. Epub 2016 Mar 24.

    PubMed 27012580
  • Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 1972 Nov-Dec;15(3):289-329. doi: 10.1016/0033-0620(72)90029-1. No abstract available.

    PubMed 4564017
  • Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dysfunction in the patient with sepsis. Curr Opin Crit Care. 2002 Oct;8(5):376-88. doi: 10.1097/00075198-200210000-00003.

    PubMed 12357104
  • Antonucci E, Fiaccadori E, Donadello K, Taccone FS, Franchi F, Scolletta S. Myocardial depression in sepsis: from pathogenesis to clinical manifestations and treatment. J Crit Care. 2014 Aug;29(4):500-11. doi: 10.1016/j.jcrc.2014.03.028. Epub 2014 Apr 5.

    PubMed 24794044
  • Rudiger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med. 2007 Jun;35(6):1599-608. doi: 10.1097/01.CCM.0000266683.64081.02.

    PubMed 17452940
  • Lopaschuk GD. Metabolic Modulators in Heart Disease: Past, Present, and Future. Can J Cardiol. 2017 Jul;33(7):838-849. doi: 10.1016/j.cjca.2016.12.013. Epub 2016 Dec 21.

    PubMed 28279520
  • Karwi QG, Uddin GM, Ho KL, Lopaschuk GD. Loss of Metabolic Flexibility in the Failing Heart. Front Cardiovasc Med. 2018 Jun 6;5:68. doi: 10.3389/fcvm.2018.00068. eCollection 2018.

    PubMed 29928647
  • Pascual F, Coleman RA. Fuel availability and fate in cardiac metabolism: A tale of two substrates. Biochim Biophys Acta. 2016 Oct;1861(10):1425-33. doi: 10.1016/j.bbalip.2016.03.014. Epub 2016 Mar 16.

    PubMed 26993579
  • Doenst T, Nguyen TD, Abel ED. Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res. 2013 Aug 30;113(6):709-24. doi: 10.1161/CIRCRESAHA.113.300376.

    PubMed 23989714
  • Drosatos K, Lymperopoulos A, Kennel PJ, Pollak N, Schulze PC, Goldberg IJ. Pathophysiology of sepsis-related cardiac dysfunction: driven by inflammation, energy mismanagement, or both? Curr Heart Fail Rep. 2015 Apr;12(2):130-40. doi: 10.1007/s11897-014-0247-z.

    PubMed 25475180
  • Carre JE, Singer M. Cellular energetic metabolism in sepsis: the need for a systems approach. Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):763-71. doi: 10.1016/j.bbabio.2008.04.024. Epub 2008 Apr 23.

    PubMed 18482575
  • Mangmool S, Denkaew T, Parichatikanond W, Kurose H. beta-Adrenergic Receptor and Insulin Resistance in the Heart. Biomol Ther (Seoul). 2017 Jan 1;25(1):44-56. doi: 10.4062/biomolther.2016.128.

    PubMed 28035081

Questions about this trial

What is this clinical trial studying?

An observational study of Septic Shock and Chronic Heart Failure, run by Centre de recherche du Centre hospitalier universitaire de Sherbrooke at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Jul 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Olivier Lesur, MD PhD (819-346-1110 ext. 14881, olivier.lesur@usherbrooke.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

FDG PET scan (time frame: 25 minutes). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05202938, which also lists 58 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2023.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in